(U)

SECURITY CLASSIFICATION OF THIS PAGE

AD-A238 276

REPORT DOCUMENTATION

Approved
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION (U)	1b. RESTRICTIVE MARKINGS NA
2a. SECURITY CLASSIFICATION AUTHORITY NA	3. DISTRIBUTION / AVAILABILITY OF REPORT Distribution Unlimited
2b. DECLASSIFICATION / DOWNGRADING SCHEDULE NA	
4. PERFORMING ORGANIZATION REPORT NUMBER(S) University of Pennsylvania	5. MONITORING ORGANIZATION REPORT NUMBER(S) NA
6a. NAME OF PERFORMING ORGANIZATION University of Pennsylvania 6b. OFFICE SYMBOL (If applicable) NA	7a. NAME OF MONITORING ORGANIZATION Office of Naval Research
6c. ADDRESS (City, State, and ZIP Code) Department of Pharmacology University of Pennsylvania School of Medicine 20th Street and Hamilton Walk, Phil. PA 19104	7b. ADDRESS (City, State, and ZIP Code) 800 N. Quincy Street Arlington VA 22217-5000
8a. NAME OF FUNDING / SPONSORING ORGANIZATION Office of Naval Research 8b. OFFICE SYMBOL (If applicable) ONR	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER N00014-88-K-0048
8c. ADDRESS (City, State, and ZIP Code) 800 N. Quincy Street Arlington, VA 22217-5000	10. SOURCE OF FUNDING NUMBERS PROGRAM ELEMENT NO. 61153N; PROJECT NO. RR04108; TASK NO. 4414807; WORK UNIT ACCESSION NO.

11. TITLE (Include Security Classification)

Inhibition of ACTH release by peptide hormones: Molecular mechanisms and possible role as anti-stress fact

12. PERSONAL AUTHOR(S)
Terry Reisine

13a. TYPE OF REPORT	13b. TIME COVERED	14. DATE OF REPORT (Year, Month, Day)	15. PAGE COUNT
Final	FROM 2/88 TO 11/90	July 2, 1991	

16. SUPPLEMENTARY NOTATION

17 COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)
FIELD	GROUP	SUB-GROUP	Stress, Corticotrophs, Anterior pituitary, Somatostatin receptor, Adrenocroticotropin
08			

19. ABSTRACT (Continue on reverse if necessary and identify by block number)

The major objectives ot this proposal were to investigate the biochemical properties of somatostatin (SRIF) receptors. We were able to solublize the receptor in an active form and have shown using immunoprecipitation procedures that the receptor is coupled to subtypes of G_i and G_o. The receptor contains sialic acid residues involved in promoting agonist binding. We have developed antibodies against the receptor. The antibodies selectively recognize the receptor by immunoblotting and can specifically immunoprecipitate the receptor from AtT-20 cells. The antibodies are being used to further investiate the physical properties of the receptor and to clone cDNA encoding the receptor from an expression library generated from AtT-20 cells. We have shown that subtypes of SRIF receptors exist and have developed selective agonists at each receptor subtype. The receptors have different distributions in brain, have distinct pharmacological and biochemical characteristics, can be differentially regulated and mediate distinct physiological actions of SRIF in brain and peripheral tissues. Attempts are underway to identify the physical basis for the functional differences in these receptor subtypes.

20. DISTRIBUTION / AVAILABILITY OF ABSTRACT	21. ABSTRACT SECURITY CLASSIFICATION
XX UNCLASSIFIED/UNLIMITED ☐ SAME AS RPT ☐ DTIC USERS	(U)
22a. NAME OF RESPONSIBLE INDIVIDUAL Dr. J.A. Maide	22b. TELEPHONE (Include Area Code) 202-696-4055 22c. OFFICE SYMBOL ONR

DD Form 1473, JUN 86 — Previous editions are obsolete. — SECURITY CLASSIFICATION OF THIS PAGE

S/N 0102-LF-014-6603

FINAL REPORT ON CONTRACT ONR N00014-88-K-0048

Principle Investigator: Dr. Terry Reisine

Contract Title: Inhibition of ACTH release by peptide hormones: Molecular mecnanisms and possible role as anti-stress factors.

Contract Period: July 1, 1988 to Oct. 31, 1990.

Research Objective: The major goal of the proposal was to investigate the mechanisms by which somatostatin (SRIF) inhibits the release of adrenocorticotropin (ACTH) in order to access whether it may be useful as a non-steriodal anti-stress factor. We proposed to investigate the structure of the SRIF receptor, and to determine whether subtypes of SRIF receptor exist.

Overall, these specific aims have been completed during the granting period.

Progress Report:

1)Physical Properties of SRIF receptors: To characterize the properties of SRIF receptors, we developed procedures to solubilize the receptor in an active form using the detergent CHAPS (He et al., 1990). The soluble receptor exhibited the same pharmacological specifity as the membrane bound receptor and maintained its coupling with GTP binding regulatory (G) proteins. Solubilization of the receptor has allowed us to identify properties of the receptor that could not be analyzed using previous procedures. We were able to identify the G proteins coupled to the receptor (He et al. 1990; Law et al., in press). This was accomplished by employing antibodies against different subtypes of the alpha subunits of G proteins (G_a) to immunoprecipitate SRIF receptor/G_a complexes. The results of these studies have shown that SRIF receptors are coupled to G_{ia1}, G_{ia3} and G_{oa} but not to G_{ia2}. Furthermore, we were able to characterize the carbohydrate structure of the receptor by lectin affinity chromatography and through the use of glycolytic enzymes (Rens-Domiano and Reisine, in press). The results of these studies have shown that sialic acid residues are associated with SRIF receptors and are necessary for the binding of agonists to the receptor. In fact, preliminary studies suggest that sialic acid residues may be localized near the ligand binding site of the receptor to promote agonist binding. This characteristic is unique among all neurotransmitter and hormone receptors. With the solublized receptor we have now been able to generate antibodies against the receptor (Theveniau et al., in press). The antibodies specifically recognize the receptor by immunoblotting and selectively immunoprecipitate the receptor. We are now using the antibodies to screen an AtT-20 cell cDNA library for clones expressing the receptor. These studies may allow us to clone the gene encoding the SRIF receptor.

2.Subtypes of SRIF receptors. Recently we have demonstrated that subtypes of SRIF receptors exist in mammalian cells (Raynor and Reisine, 1989; Martin et al., 1991, Raynor et al., in press; Raynor and Reisine, in press). One receptor has high affinity for SRIF and a potent SRIF agonist MK 678 and is refered to as the $SRIF_1$ receptor. The other receptor ($SRIF_2$ receptor) has high affinity for a different SRIF agonist CGP 23996 but has no affinity for MK 678. We have now identified a series of structural analogs of MK 678 or CGP 23996 that are highly selective at each receptor subtype. The receptors have different distributions in brain and are coupled to different cellular effector systems. The $SRIF_1$ receptor is coupled to K^+ channels, the $SRIF_2$ receptor is coupled to adenylyl cyclase and both receptor subtypes are coupled to Ca^{++} channels. The receptor subtypes can also be differentially regulated. In previous studies we were able to solublize the $SRIF_1$ receptor (He et al., 1990). Under those same conditions, the $SRIF_2$ receptor remains membrane bound. Presently, we are developing procedures to solubilze both receptor so as to physically separate them so as to characterize their properties separately. The receptor subtypes appear to mediate distinct physiological actions an behaviors of SRIF. We have

been able to inject MK 678 into the nucleus accumbens and stimulate locomotor activity (Raynor et al., 1990). SRIF has a similar effect but CGP 23996 has no effect, indicating that the locomotor enhancing effects of SRIF are selectively mediated by $SRIF_1$ receptors. We have now begun studies to investigate the cognitive effects of SRIF. We can deplete brain SRIF levels with the drug cysteamine and induce cogntive impairments, as measured in the eight arm radial maze test. The cognitive impairments can be completely reversed by icv injection of MK 678. We are presently testing CGP 23996 in the same behavioral paradigm to determine whether the cognitive enhancing effects of SRIF are also selectively mediated by $SRIF_1$ receptors.

Inventions: None

Personnel: Henry Wang, Karen Raynor, Susan Law.
Women or minorities-2, Non-citizens-1.

Publications:

1. Thermos, K. and Reisine, T.: Somatostatin receptor subtypes in the clonal anterior pituitary cell lines AtT-20 and GH_3. Mol. Pharmacol. 33:370-377, 1988.

2. He, H.T., Johnson, K., Thermos, K. and Reisine, T.: Purification of a putative brain somatostatin receptor. Proc. Natl. Acad. Sci. 86:1480-1484, 1989.

3. Wang, H., Bogen, C., Reisine, T. and Dichter, M.: Somatostatin-14 and somatostatin-28 induce opposite effects on potassium currents in rat neocortical neurons. Proc. Natl.Acad. Sci. 86:9616-9620, 1989.

4. Raynor, K. and Reisine, T.: Analogs of somatostatin selectively label distinct subtypes of somatostatin receptors in rat brain. J. Pharmacol. Expt. Therap. 251:510-517, 1989.

5. Thermos, K., He, H.T., Wang, H., Margolis, N., and Reisine, T.: Biochemical properties of brain somatostatin receptors. Neurosci. 31:131-141, 1989.

6. White, M. and Reisine, T.: Expression of functional pituitary somatostatin receptors in Xenopus oocytes. Proc. Natl. Acad. Sci. 87:133-136, 1990.

7. He, H.T., Rens-Domiano, S., Martin, J.M., Law, S., Borislow, S., Woolkalis, M., Manning, D. and Reisine, T.: Solubilization of active somatostatin receptors from rat brain. Mol. Pharmacol. 37:614-621, 1990.

8. Thermos, K., Meglasson, M., Nelson, J., Lounsbury, K. and Reisine, T.:Pancreatic beta cell somatostatin receptors. Am. J. Physiol. 259:E216-E224, 1990.

9. Wang, H., Reisine, T. and Dichter, M.: Somatostatin-14 and somatostatin-28 inhibit calcium currents in rat neocortical neurons. Neurosci. 38:335-342, 1990.

10. Wang, H., Dichter, M. and Reisine, T.: Lack of cross-desensitization of somatostatin-14 and somatostatin-28 receptors coupled to potassium channels in rat neocortical neurons. Mol. Pharmacol. 38:357-361, 1990.

11. Reisine, T.: Pertussis toxin in the analysis of receptor mediated signal transduction. Biochem. Pharmacol. 39:1499-1504, 1990.

12. Reisine, T.: Cellular mechanisms of somatostatin inhibition of calcium influx in the anterior pituitary cell line AtT-20. J. Pharmacol. Expt. Therap. 254:646-651, 1990.

13. Reisine, T., He, H.T., Rens-Domiano, S., Martin, J.M., Raynor, K., Borislow, S. and Thermos, K.: Biochemical properties of somatostatin receptors. Metabolism 39:70-73, 1990.

14. Dichter, M., Wang, H. and Reisine, T.: Electrophysiological effects of somatostatin-14 and somatostatin-28 on mammalian CNS neurons. Metabolism 39:86-90, 1990.

15. Nicolaou, K.C., Salvino, J., Raynor, K., Pietranico, S., Reisine, T., Freidinger, R. and Hirschmann, R.: Design and synthesis of a peptidomimetic employing β-D-glucose for scaffolding. In Peptides, eds J. Rivier and G. Marshall, ESCOM Leiden, pp. 881-884, 1990.

16. Martin, J.L., Chesselet, M.F., Raynor, K., Gonzales, C. and Reisine, T.: Differential distribution of somatostatin receptor subtypes in rat brain revealed by newly developed somatostatin analogs. Neurosci. 41:581-593, 1991.

17. Reisine, T., Rens-Domiano, S., Law, S. and Martin, J.M.: Purification of somatostatin receptors. In: Methods in Neuroscience, ed P.M. Conn. Academic Press, New York, vol. 5, pp. 215-224, 1991.

18. Raynor, K., Wang, H., Dichter, M., and Reisine, T.:Subtypes of somatostatin receptors couple to multiple cellular effector systems. Mol. Pharmacol. (in press).

19. Law, S., Manning, D. and Reisine, T.: Identification of the subunits of GTP binding proteins coupled to somatostatin receptors. J. Biol. Chem. (in press).

20. Rens-Domiano, S. and Reisine, T.: Structural analysis and functional role of the carbohydrate component of somatostatin receptors. J. Biol. Chem. (in press).

21. Reisine, T. and Law, S.: Pertussis toxin in the analysis of receptor mechanisms. In: Methods in Neurosci., ed. P.M. Conn, Academic Press, New York, (in press)

22. Spanevello, R., Hirschmann, R., Raynor, K., Reisine, T. and Nutt, R.: Synthesis of novel, highly potent cyclic-hexapeptide analogs of somatostatin. Potential application of orthogonal protection for affinity chromatography. Tetrahedron Lett. (in press).

23. Raynor, K., Coy, D. and Reisine, T.:Analogs of somatostatin bind selectively to brain somatostatin receptor subtypes. J. Pharmacol. Expt. Therap. (in press).

24. Raynor, K. and Reisine, T.: Differential coupling of somatostatin$_1$ receptors to adenylyl cyclase in the rat striatum vs. the pituitary and other regions of the rat brain. J. Pharmacol. Expt. Therap. (in press).

Awards/Fellowships: None.

A-1